Annual report [Section 13 and 15(d), not S-K Item 405]

Acquisition of CorHepta (Additional Information) (Details)

v3.26.1
Acquisition of CorHepta (Additional Information) (Details) - USD ($)
 12 Months Ended
Feb. 21, 2025
Jan. 25, 2023
Dec. 31, 2025
Dec. 31, 2024
Business Combination [Line Items]        
Shares Unvested     4,149,252  
Change in fair value of contingent consideration $ 4,435,443   $ 1,373,942 $ 0
Written off     7,357,294  
Common Stock        
Business Combination [Line Items]        
Issuance of common stock, Shares   466,799    
CorHepta Pharmaceuticals [Member]        
Business Combination [Line Items]        
Date of acquisition agreement Feb. 21, 2025      
Change in fair value of contingent consideration     1,373,942  
Consideration transferred     $ 7,400,000  
CorHepta Pharmaceuticals [Member] | Common Stock        
Business Combination [Line Items]        
Issuance of common stock, Shares 4,979,101      
Shares vested 829,849   829,849  
Shares representing contingent consideration 2,489,030   1,493,415  
Shares representing post-merger compensation expense 1,660,222      
Shares Unvested 1,493,415